JP2018511555A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511555A5
JP2018511555A5 JP2017538667A JP2017538667A JP2018511555A5 JP 2018511555 A5 JP2018511555 A5 JP 2018511555A5 JP 2017538667 A JP2017538667 A JP 2017538667A JP 2017538667 A JP2017538667 A JP 2017538667A JP 2018511555 A5 JP2018511555 A5 JP 2018511555A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
modified oligonucleotide
wing segment
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017538667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/019728 external-priority patent/WO2016138355A1/en
Publication of JP2018511555A publication Critical patent/JP2018511555A/ja
Publication of JP2018511555A5 publication Critical patent/JP2018511555A5/ja
Pending legal-status Critical Current

Links

JP2017538667A 2015-02-27 2016-02-26 リポジストロフィー集団におけるアポリポタンパク質C−III(ApoCIII)発現の調節 Pending JP2018511555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126439P 2015-02-27 2015-02-27
US62/126,439 2015-02-27
PCT/US2016/019728 WO2016138355A1 (en) 2015-02-27 2016-02-26 Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations

Publications (2)

Publication Number Publication Date
JP2018511555A JP2018511555A (ja) 2018-04-26
JP2018511555A5 true JP2018511555A5 (https=) 2020-06-18

Family

ID=56789093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017538667A Pending JP2018511555A (ja) 2015-02-27 2016-02-26 リポジストロフィー集団におけるアポリポタンパク質C−III(ApoCIII)発現の調節

Country Status (13)

Country Link
US (2) US20180245076A1 (https=)
EP (1) EP3270931A4 (https=)
JP (1) JP2018511555A (https=)
KR (1) KR20170122769A (https=)
CN (1) CN107405358A (https=)
AU (1) AU2016222548A1 (https=)
BR (1) BR112017015307A2 (https=)
CA (1) CA2977971A1 (https=)
HK (1) HK1248522A1 (https=)
IL (1) IL253346A0 (https=)
MX (1) MX2017011009A (https=)
RU (1) RU2737719C2 (https=)
WO (1) WO2016138355A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
IL300882A (en) * 2020-10-02 2023-04-01 Ionis Pharmaceuticals Inc Methods for reducing APOCIII expression
CN117580953B (zh) * 2021-07-16 2025-07-18 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
EP3009136A1 (en) * 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
CN107854478A (zh) * 2011-04-27 2018-03-30 Ionis制药公司 载脂蛋白ciii(apociii)表达的调节
AU2014216137B2 (en) * 2013-02-14 2018-05-10 Ionis Pharmaceuticals, Inc. Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
WO2014205449A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
US20150045431A1 (en) * 2013-08-06 2015-02-12 Amarin Pharmaceuticals Ireland Limited Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy

Similar Documents

Publication Publication Date Title
JP2014516516A5 (https=)
JP2020111594A5 (https=)
JP2016513110A5 (https=)
RU2015151200A (ru) Композиции и способы модулирования экспрессии аполипопротеина (а)
JP2014513954A5 (https=)
JP2018511555A5 (https=)
ES3050007T3 (en) Oligomers and oligomer conjugates
JP2014511686A5 (https=)
JP2017505116A5 (https=)
JP2005503142A5 (https=)
JP2014530004A5 (https=)
JP6313789B2 (ja) リポタンパク質リパーゼ欠損(lpld)集団におけるアポリポタンパク質c−iii(apociii)発現の調節
JP2012050438A5 (https=)
JP2017513469A5 (https=)
Singerman Combination therapy using the small interfering RNA bevasiranib
JP2016522817A5 (https=)
JP2013526860A5 (https=)
RU2708672C1 (ru) Конъюгаты цитарабина для лечения рака
JP2020511155A5 (https=)
JP2016171800A5 (https=)
IL264288B (en) Methods and compositions for modulating apolipoprotein(a) expression
JP2017008059A (ja) アポリポタンパク質ciii(apociii)発現の調節
JP2013538560A5 (https=)
JP2009508527A5 (https=)
JP2015536132A5 (https=)